Related Experiment Video

Updated: Jun 22, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced

Jeannette Gerspach1, Klaus Pfizenmaier, Harald Wajant

  • 1Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany. jeanette.gerspach@izi.uni-stuttgart.de

Biofactors (Oxford, England)
|June 2, 2009
PubMed

Insights

Tumor necrosis factor (TNF) shows promise for cancer therapy due to its tumor-killing ability. Researchers are developing engineered TNF variants to minimize side effects and enhance anti-tumor efficacy for broader clinical application.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Tumor necrosis factor (TNF) is a pleiotropic cytokine with diverse cellular functions, including regulating proliferation, migration, angiogenesis, differentiation, apoptosis, necrosis, and survival.
  • TNF's potent tumor necrosis-inducing capability has long made it a target for antitumor therapy.
  • Current clinical use of TNF is limited to isolated limb perfusion for soft tissue sarcoma due to significant systemic proinflammatory effects.

Purpose of the Study:

  • To review advancements in improving the efficacy of TNF for cancer treatment.
  • To explore strategies for reducing systemic side effects while retaining anti-tumor activity.

Main Methods:

  • Genetic engineering of TNF variants.
  • Tumor targeting strategies for TNF delivery.
  • Development of prodrug concepts for TNF activation.

Main Results:

  • Development of tailor-made TNF variants over the past decade aims to reduce systemic activity.
  • Strategies focus on enhancing anti-tumor effects without compromising safety.

Conclusions:

  • Significant progress has been made in optimizing TNF for cancer therapy through genetic engineering, targeted delivery, and prodrug approaches.
  • These advancements hold promise for overcoming the limitations of traditional TNF-based treatments and expanding its clinical utility in oncology.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...